Shanghai Tolo Biotech Co., Ltd (Tolo) aims to fight global health threat by cutting-edge technologies. Tolo owns the CRISPR-Cas12 diagnostic method patent and recently developed the Cas12-based HOLMES™ rapid nucleic acid detection platform, and is now promoting its application in areas such as POCT, agriculture, food safety and home use testing. Tolo also develops and manufactures core molecular diagnostic enzymes including Cas proteins, and provides CDMO services for both academic and industry.